All Tessera Therapeutics articles
-
NewsTessera's gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
-
ArticleTessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency
As the industry looks beyond CRISPR to safely introduce therapeutic genomic changes anywhere in the body, in vivo gene editing holds immense potential to address diseases with a genetic basis. Boston-based biotech Tessera Therapeutics is pioneering the next generation of genetic medicines with its Gene Writing™ platform. At this year’s ...